Core Viewpoint - The weight loss drug market is emerging as a significant growth opportunity in the pharmaceutical industry, comparable to the technology sector, with Eli Lilly and Viking Therapeutics as key players [1][2]. Eli Lilly - Eli Lilly leads the weight loss drug market with a 60% share, driven by its products Mounjaro and Zepbound, which have shown triple-digit revenue growth [5][13]. - The company entered the GLP-1 drug market after Novo Nordisk and has focused on increasing manufacturing capacity to meet demand [4][5]. - Lilly's oral weight loss drug is currently under regulatory review, potentially expanding its market presence [6]. Viking Therapeutics - Viking Therapeutics is advancing its candidate VK2735 into phase 3 trials, with promising results suggesting it could compete effectively with Lilly and Novo's offerings [8][9]. - The company has another candidate targeting amylin and calcitonin receptors, which are important for metabolism [10]. - Demand for weight loss drugs is high, providing Viking with an opportunity to capture market share if its trials are successful [10]. Investment Considerations - Both Eli Lilly and Viking Therapeutics are viewed as strong investment opportunities in the weight loss drug market, with Lilly currently generating significant revenue and Viking showing potential for future growth [13][15]. - Lilly's stock has seen a decline of about 8% this year, trading at 28 times forward earnings estimates, while Viking's stock has increased by approximately 2% this year [13][14]. - The upcoming regulatory decision on Lilly's oral weight loss drug could serve as a catalyst for its stock price [15].

Core Viewpoint - The J. M. Smucker Company (NYSE:SJM) is experiencing positive stock performance and analyst upgrades, despite cautious fiscal commentary for 2026 [2]. Group 1: Stock Performance - Shares of The J. M. Smucker Company are up by 6% over the past year and by 20% year-to-date [2]. - JPMorgan raised the share price target to $122 from $121, maintaining an Overweight rating [2]. - TD Cowen increased the target price to $112 from $105, keeping a Hold rating, citing cautious fiscal 2026 commentary [2]. Group 2: Financial Results - The company reported $2.34 billion in revenue and $2.38 in adjusted earnings per share, surpassing analyst estimates of $2.33 billion and $2.26 respectively [2]. Group 3: Market Influences - Jim Cramer highlighted the impact of weight loss drugs on food company sales, mentioning the role of activist Elliott Management in supporting The J. M. Smucker Company [4].

Group 1 - The S&P 500 has entered the third year of a bull market, finishing the previous year with a double-digit gain, resulting in a three-year increase of 78% [1] - Investors have shown particular optimism towards high-growth sectors, including artificial intelligence, quantum computing, and weight loss drugs, with notable stocks like Nvidia, IonQ, and Eli Lilly experiencing significant price increases [1] - The Federal Reserve's interest rate cuts have contributed to a positive investor sentiment, as lower rates ease consumer financial pressure and facilitate corporate borrowing [2] Group 2 - The Shiller CAPE ratio, which measures stock price relative to earnings per share, surpassed 40 earlier this year, a level only previously reached during the dot-com boom in 2000 [2] - Concerns regarding the sustainability of high valuations for AI stocks emerged in late 2025, leading to stock price declines for these companies [4] - Recent uncertainties about the pace of interest rate cuts and the effectiveness of high spending by AI companies have contributed to a cautious investor sentiment [5]

Sports quarter results out from Eli Liy. $7.54% a share beat estimates of 667 a share. Uh revenue of 19.3% billion.All right, we're going to have to figure this out. Look at that stock. Uh up 7% back over $1,000 of 17.9% billion.Um fourth quarter volumes rose 76%. Realized prices though fell 5%. Zepbound and Monaro sales more than doubled year-over-year.and those were well above expectations and that the company also uh issued upbeat fullear guidance. So it's the opposite thing we're looking for here. What ...

Core Viewpoint - The U.S. stock market experienced a collective decline, with major indices such as the Dow Jones falling by 0.34%, the Nasdaq by 1.43%, and the S&P 500 by 0.83% [1] Sector Performance - Technology stocks saw significant declines, with Broadcom dropping over 3%, and major players like Microsoft, Nvidia, and Meta each falling by more than 2% [1] - In contrast, sectors such as rare earths, non-ferrous metals, and precious metals showed strong performance, with gold resources increasing by over 20%, Southern Copper rising by more than 11%, Americas Silver up over 8%, and Pan American Silver gaining over 5% [1] - Application software, cryptocurrency, and weight loss drug stocks faced the largest declines, with Novo Nordisk falling over 14%, Coinbase and Circle each dropping over 4%, and Eli Lilly and Pfizer decreasing by more than 3% [1] Notable Company Movements - Walmart's stock rose by 2.94%, marking a significant milestone as its market capitalization surpassed the $1 trillion mark for the first time [1]

Core Insights - The weight loss market is currently dominated by two brands: Wegovy from Novo Nordisk and Zepbound from Eli Lilly, with both companies poised for further growth through new approvals [2][11] Novo Nordisk - Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics GLP-1 hormones, aiding in insulin regulation and satiety [4] - The company is seeking approval for CagriSema, a dual agonist that has shown better performance than semaglutide in clinical trials, potentially becoming a new growth driver [5] - Despite a competitive mean weight loss of 22.7% reported for CagriSema, it did not meet the company's expectations of 25% in phase 3 studies [11] - Novo Nordisk's market value has decreased by more than half over the past two years, but its pipeline may still capitalize on the expanding weight loss market [12] Eli Lilly - Eli Lilly's Zepbound is gaining market share, and the company has reported positive phase 3 results for orforglipron, a next-generation anti-obesity medication [11] - Orforglipron is a daily oral pill, making it easier for patients compared to weekly injections of Wegovy and Zepbound, which could enhance its market appeal [7][8] - The approval process for orforglipron may be expedited due to its receipt of a National Priority Voucher, potentially allowing for a quicker market entry [8] - Eli Lilly's retatrutide has demonstrated a mean weight loss of 28.7% in phase 3 studies, indicating a strong competitive position in the market [12]

Core Insights - Eli Lilly has achieved strong returns due to its advancements in weight management, positioning itself as a leader in this market [1] - The company is not resting on its laurels and continues to innovate, suggesting it may outpace competitors [1] Competitive Landscape - Novo Nordisk is the only significant competitor to Eli Lilly in the weight loss drug market, with its product Wegovy generating billions in sales [2] - Novo Nordisk is seeking label expansions and has requested FDA approval for a higher dose of semaglutide, the active ingredient in Wegovy [3][4] Product Performance - Eli Lilly's Zepbound has demonstrated superior average weight loss compared to Wegovy in clinical trials, generating $9.3 billion in revenue in the first nine months of 2025, while Wegovy generated approximately $9 billion [5] - Novo Nordisk's pipeline includes Amycretin, which is in phase 3 studies, but Eli Lilly's pipeline remains stronger with promising candidates like orforglipron and retatrutide [6][7] Market Position - Eli Lilly is clearly leading the weight loss market, with its current and future products positioning it ahead of competitors [8] - Novo Nordisk's CagriSema, which achieved a mean weight loss of 22.7%, is under regulatory review but still falls short compared to Eli Lilly's offerings [9]

Group 1: Investment Themes for 2026 - Citrini Research has identified key investment themes for 2026, focusing on automation, weight loss drugs, and female consumer spending [5][6] - The firm has developed a "Bureaucracy Score" and a "Margin Optionality Score" to screen companies that could benefit from AI-induced layoffs, indicating a bullish outlook on stocks that can reduce headcount effectively [6] Group 2: Stock Picks Related to AI Job Losses - Over thirty firms have been identified as potential beneficiaries of AI job losses, with notable mentions including Accenture, IBM Corp., Zoom Video, Target, United Parcel Service, Intuit, and Dollar General [8][6] - The focus is on companies that can streamline operations and improve profitability through automation [6] Group 3: Slop Bowl Automation - Slop bowl chains are expected to be early adopters of back-of-house automation, which will help reduce labor costs and enhance profit margins [9] - Companies like Chipotle and Cava are highlighted as likely to experience significant operational improvements due to automation [9] Group 4: Weight Loss Drug Market - The popularity of GLP-1 drugs such as Ozempic and Wegovy is creating investment opportunities for companies catering to users looking to maintain weight loss after discontinuing these medications [11] - Potential stock picks in this sector include Chipotle, Cava, Sweetgreen, Fanuc Corporation, Circus SE, and Compass Group [12]

Earlier this week, Unilver spun off its ice cream business as the Magnum Ice Cream Company, MICC, for all you home gamers, creating the first pure play ice cream stock that I can recall. Unilver announced this nearly two years ago, but to be honest, I really didn't pay a lot of attention to it. So, it took me by surprise when I came into work yesterday to see this multi-story tall banner of ice cream outside the New York Stock Exchange with free samples flowing ON THE FLOOR.KLONDIKE BARS for all. And still ...

But what Lily is trying to do today is stay competitive in the direct to consumer space for its weight loss drugs, especially following similar moves by Nova Nordis two weeks ago. And so what Lily is doing today is specifically cutting the cash price of single dose vials of Zepbound on its direct to consumer website, Lily Direct. Okay.And what's different with this compared to the Trump deal is that the Trump deal focuses on a totally different form of Zepbound, which is a multi-dosese pen that has yet to w ...